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ABSTRACT 
 
 
Background 
To ensure effective monitoring of pulmonary arterial hypertension (PAH), a simple, reliable 
assessment of exercise capacity, applicable over a range of disease severity is needed. The 
study aim was to assess the ability of the incremental shuttle walking test (ISWT) to correlate 
with disease severity, measure sensitivity to change and predict survival in PAH.  
 
Methods 
418 treatment-naïve patients with PAH, with baseline ISWT within 3 months of cardiac 
catheterization, were enrolled. The clinical validity and prognostic value of the ISWT distance 
was assessed at baseline and 1 year.  
 
Results 
ISWT distance was found to correlate at baseline with World Health Organisation functional 
class, Borg score and haemodynamics without a ceiling-effect (all p<0.001). Walking 
distance at baseline and after treatment predicted survival; the area under the receiver 
operator characteristic curve for the ability of the ISWD to predict mortality was 0.655 
(95%CI 0.553-0,757), p=0.004 at baseline, and 0.737 (0.643-0.827), p<0.001 at 1 year 
following initiation of treatment.  Change in ISWD also predicted survival (p=0.04). Heart rate 
(HR) and systolic blood pressure (SBP) parameters reflecting autonomic response to 
exercise (highest HR, change in HR, HR recovery at 1 minute>18, highest 6%3ǻ6%3DQG
3minute SBP ratio) were significant predictors of survival (all p<0.05). 
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Conclusions 
In patients with PAH the ISWT is simple to perform, allows assessment of maximal exercise 
capacity, is sensitive to treatment effect, predicts outcome and has no ceiling-effect. In 
addition, we have also shown that measures of autonomic function made post-exercise 
predict survival in PAH.  
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INTRODUCTION 
 
Pulmonary arterial hypertension (PAH) is a life-threatening condition characterised by 
vascular proliferation and remodelling, leading to an increase in pulmonary artery pressure.1 
This increased afterload results in a reduction in cardiac output and decreased tissue 
oxygen delivery so limiting exercise capacity. Assessment of exercise capacity, therefore, 
has the potential to play a role in defining the severity of PAH and monitoring treatment but 
this is crucially dependent on the exercise test reflecting disease severity.  
 
Due to its simplicity, the six-minute walking test (6MWT) is used to monitor patients in the 
clinic and assess the efficacy of new therapies. More recently the 6MWT has also been used 
to assess autonomic function in patients with PAH, and impaired heart rate recovery has 
been shown to predict an increased rate of clinical worsening.2,3 However, concerns have 
been raised regarding the use of the 6MWT both in clinical practice and in trials of new 
therapies.4-8 ,QSDUWLFXODUD³FHLOLQJ-HIIHFW´KDVEHHQQRWHGZKHUH6MWT distance (6MWD) 
no longer reflects maximal oxygen aerobic capacity9-11 or disease severity12 and may, 
therefore, be unable to identify clinically important changes in haemodynamic parameters.12-
15
 In addition, change in 6MWD does not explain a large proportion of observed treatment 
effect.16-18 
 
The Incremental Shuttle Walk Test (ISWT) is an externally-paced symptom-limited 12-level 
test requiring the patient to increase their speed every minute. The incremental shuttle 
walking distance (ISWD) correlates with disease severity and is sensitive to change in a 
number of respiratory diseases.19  The ISWT has potential advantages in assessment of 
cardiac dysfunction since in chronic heart failure the ISWT is a better predictor of survival 
than the 6MWT.20 A small study in pulmonary hypertension also noted that ISWD correlated 
more closely with peak oxygen consumption than 6MWT distance.21 The ISWT has therefore 
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been proposed as an alternative field walking test to the 6MWT in PAH,22,23 however, there 
are no long-term data on the prognostic value of the ISWT or its sensitivity to change.   
 
The aim of this study, was to undertake the first assessment of the ability of the ISWT to 
reflect disease severity, measure sensitivity to change and assess prognostic value in 
patients with PAH. In addition, we have assessed autonomic function during and 
immediately post exercise, using heart rate and blood pressure changes, and assessed the 
impact of autonomic function on survival in PAH. 
  
7 
 
METHODS 
 
Data were retrieved from the ASPIRE registry (Assessing the Spectrum of Pulmonary 
hypertension Identified at a REferral centre) for consecutive patients diagnosed with 
pulmonary hypertension between 2001-10.24 The diagnostic evaluation and clinical 
classification of these patients have been described previously.24 For inclusion patients were 
required to have PAH and a baseline ISWT within 3 months of cardiac catheterization and 
prior to the introduction of targeted PAH therapy. Ethical approval was granted by the North 
Sheffield Research Ethics Committee (Reference No. 06/Q2308/8). 
 
Incremental Shuttle Walk Test 
The ISWT was performed according to the method of Singh et al.25 No practice walk was 
performed and no supplemental oxygen used. Patients usually receiving supplemental 
oxygen performed the test breathing room air. Breathlessness and blood pressure were 
measured at rest and at the end of the test. Heart rate was measured throughout the test. To 
assess autonomic function, change in heart rate, heart rate recovery at 1 minute post-
exercise (HRR1), change in systolic blood pressure (SBP), and the systolic blood pressure 
three minute ratio were calculated. Predicted ISWD (ISWD%pred) was calculated using the 
equation described by Probst et al.26 (See online supplementary data , available online 
at www.jhltonline.org). 
 
Follow-up 
Treatment of PAH was in accordance with UK national commissioning policy based on 
international guidelines. Mortality was ascertained at the census point via the NHS enhanced 
reporting service. Data were collected for patients at 12 months (+/-2 months) post-
diagnosis. 
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Statistical analysis  
 
Statistical analysis was performed using IBM SPSS Statistics v19 (SPSS, Chicago, IL, USA). 
Continuous variables were described by mean±standard deviation. 3HDUVRQ¶VFRUUHODWLRQ
test was used to assess correlations between incremental shuttle walk test distance and 
haemodynamic parameters and was tested for 2-sided significance. Multiple comparisons 
between groups were performed using ANOVA for parametric data. Event (death or 
transplantation)-free survival from date of diagnosis was estimated using the Kaplan±Meier 
method with comparison between groups performed by the log-rank test. The accuracy of 
the prognostic parameters was estimated using receiver operating curves ROC. A p-value of 
<0.05 was deemed statistically significant.   
 
Stratification of patients  
The ISWT has 12 levels. We used a model with 5 pre-specified Bands based on walking 
distance/maximal walking speed that were the best fit for a Gaussian distribution. Band 1: 
Level 1, 0-30m, equivalent to 0.50 m/s, 14% of patients; Band 2:Level 2 and 3, 40-120m, 
0.67-0.84 m/s, 28% of patients; Band 3:Level 4 and 5, 130-250m, 1.01-1.18 m/s, 28% of 
patients ; Band 4: Level 6 and 7, 260-420m, 1.35-1.52m/s, 22% of patients ; Band 5: Level 
8-12, 430-1020m, 1.69-2.37 m/s, 8% of patients.  ISWD%pred was also stratified into 5 
Bands.  To ensure the ISWT bands did not result from over-fitting of the data, resampling 
techniques were used to validate the utility of ISWT distance as a predictor of mortality using 
sub-samples. At follow-up improvement was defined as increase >40m, decline decrease 
>20m and the remaining patients defined as stable.27,28 
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RESULTS 
 
Between 2001-10, 418 patients had a diagnosis of PAH and a baseline ISWT within 3 
months of cardiac catheterization and prior to the introduction of targeted-therapy. Baseline 
characteristics are presented in table1. There were high levels of data completeness for all 
parameters studied (>90%). Median distance walked at baseline was 150m and median time 
to complete the walk was 3.67 minutes. The ISWT was found to be a safe test with no major 
adverse event (death, need for cardiopulmonary resuscitation, arrhythmia, causing collapse) 
reported (n=10,979 tests completed during this study period). 
 
 
Baseline ISWD and clinical correlates 
Absolute baseline ISWT distance correlated significantly with haemodynamic parameters 
including, right atrial pressure (RAP), pulmonary vascular resistance (PVR), cardiac output, 
cardiac index and mixed venous oxygen saturation, (p all<0.001). ISWT distance also 
correlated with baseline resting Borg score and World Health Organization (WHO) functional 
class, SDOO2QH-way ANOVA demonstrated a highly significant relationship 
(p<0.001) for ISWD Band (Figure 1) with WHO functional class, baseline resting Borg score, 
and baseline pulmonary haemodynamic parameters across all Bands. There were significant 
differences in haemodynamics even between the top two bands with Band 5 having 
significantly lower PVR (mean±sd 6.2±3.0 vs 8.9±4.7 Wood unit, p=0.04) and mRAP 
(5.5±3.3 vs 8.3±4.4 mmHg, p=0.002) than Band 4.  
 
Baseline ISWD and survival 
Kaplan-Meier survival analysis demonstrated that baseline ISWT distance predicted survival 
with no ceiling-effect across the 5 Bands (p<0.001), (Figure 2A). This pattern was also 
evident in PAH subgroups: IPAH (p<0.001); PAH-SSc (p<0.001), and older PAH patients 
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>60 years of age (<0.001) (Figure 3). Internal validation of the banding model found that 
ISWD band significantly predicted survival in patients diagnosed at different times and in all 
random subgroups examined, (p all <0.05). A similar pattern with no ceiling-effect was seen 
across the 5 bands of ISWD%pred bands (p<0.001). ISWD%pred was not a better predictor 
of survival than absolute distance walked with an area under the Receiver Operator 
Characteristic curve (AUROC) of 0.646 (95%CI 0.594-0.699) and 0.690 (0.639-0.740) 
respectively, p>0.05.  The sensitivity and specificity of different ISWD cut-off points to predict 
mortality are shown in table 2.      
 
Follow-up and change in ISWD  
Follow-up ISWT distance was a significant predictor of survival at 1 year (Figure 2B). 
Analysing data only from patients who had repeated tests at 1 year,  AUROC (95%CI) was 
0.655 (0.553-0,757), p=0.004 at baseline, and 0.737 (0.643-0.827), p<0.001 at 1 year 
following initiation of treatment. Compared to ISWD at baseline, ISWD at one year was a 
significantly better predictor of long term outcome (p<0.05) and the sensitivity and specificity 
of death at 2 years post-diagnosis associated with ZDONLQJ120m at baseline was 15/93 
compared WRDVVRFLDWHGZLWKZDONLQJPDW year. 
 
0HDQǻ,6:'ZDV+12.2m at 1 year (SSDLUHGWWHVWǻ,6:'GLIIHUHGVLJQLILFDQWO\
DFURVVWKHEDQGVSZLWKDQRYHUDOOPHDQǻ,6:'at 1 year in Band 1 of +71m 
FRPSDUHGZLWKDQRYHUDOOPHDQǻ,6:D in Band 5 of -23m. However, analysis of individual 
data showed that response to therapy was varied.  Approximately 30% had an improved 
walking distance of >40m, 40% remained stable and 30% declined by more than 20m. This 
pattern of response was seen acroVVWKH%DQGV7KHPHGLDQǻ,6:'Ior improvers was 
similar across the Bands. However, for dHFOLQHUVWKHPHGLDQǻ,6:'YDULHGVLJQLILFDQWO\
across the Bands, increasing with increasing baseline distance (p<0.05), (table 3).  
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ǻ,6:'ZDVIRXQGWRFRUUHODWHVLJQLILFDQWO\ZLWKFKDQJHVLQhighest HR, highest SBP and 
resting Borg score at 1 year.  Univariate Cox survival analysis demonstrated that absolute 
change from baseline was a significant predictor of survival and KM survival curves showed 
significant survival differences between groups. However, multivariate Cox proportional 
KD]DUGVDQDO\VLVGHPRQVWUDWHGWKDWDOWKRXJKǻ,6:'SUHGLFWHGVXUYLYDOHYHQZKHQDGMXVWHG
for baseline ISWD (p<0.001), when adjusted for follow-XS,6:'ǻ,6:D was no longer a 
significant predictor (p=0.75). Survival difference between improvers and decliners was 
reflected by mean distance walked at 1 year (304m/152m) (p<0.001). Greatest percentage 
FKDQJHIURPEDVHOLQHGLVWDQFHǻ,6:'RFFXUUHGLQSDWLHQWVZLWh a low baseline ISWD 
(Supplemental Table 1). Examining the relationship between %changeISWD and follow-up 
ISWD (Supplemental Figure 1), survival was again found to reflect distance walked at follow-
up, rather than a linear relationship with %change. Cox proportional hazards analysis also 
VKRZHGWKDWǻ,6:'IURPEDVHOLQHZDVQRWSUHGLFWLYHRIVXUYLYDOS!  
 
Autonomic response to exercise 
Univariate Cox analysis demonstrated that parameters reflecting autonomic response to 
exercise (highest HR, ǻHR, +55!+LJKHVW6%3ǻ6%3DQGPLQXWH6%3UDWLRZHUH
significant predictors of survival and Kaplan-Meier analysis using thresholds derived from 
ROC analysis also showed significant survival benefit for improved chronotropic and blood 
pressure response (p all<0.05) (Figure 4). All these parameters correlated significantly with 
ISWD, and when corrected for ISWD the chronotropic and blood pressure responses were 
no longer significant independent prognostic predictors. Multivariate Cox analysis including 
haemodynamic data showed that ISWD remained an independent predictor of survival 
(p<0.001) 
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DISCUSSION 
 
We have demonstrated in patients with pulmonary arterial hypertension that distance walked 
using the incremental shuttle walking test correlates with pulmonary haemodynamics, WHO 
functional class and resting Borg score and predicts prognosis both at baseline and at 
subsequent follow-up, all without a ceiling-effect. Furthermore, we have also shown that 
measures of autonomic function made immediately post exercise predict survival in PAH. 
These attributes of the incremental shuttle walking test make it an attractive field walking test 
in PAH.  
 
Currently two exercise tests are used in PAH: the 6MWT which is an un-encouraged test 
and CPET which is an incremental maximal test. Because of the sub-maximal nature of the 
6MWT it loses its ability to reflect maximal oxygen aerobic capacity9-12 and pulmonary 
haemodynamic severity11,12 in patients with milder disease. Furthermore, changes in 
haemodynamic parameters may not be reflected by alteration in 6MWT distance.12-15 
Nonetheless the 6MWT has been useful in clinical trials and clinical practice having the 
benefit of being evaluated over several decades.  CPET provides information on the 
aetiology of exercise limitation,29 provides prognostic information,230 reflects haemodynamic 
severity and unlike the 6MWT reflects maximal oxygen uptake even in mild disease.  
However, routine use of CPET is challenging and when used in a randomised controlled trial 
it was unable due to its complexity to demonstrate a treatment effect.31 The ISWT shares 
benefits of both the 6MWT and CPET in that it is simple and quick to perform (median time 
3.67 minutes) but also has the benefits of an incremental nature to maximum exercise 
capacity. Despite the test protocol requiring the patient to walk or run at increasing speed, 
which may be thought challenging for older patients or those with mobility problems, ISWD 
was able to predict survival in older subjects (age >60) and patients with systemic sclerosis. 
Additionally, the test uses a 10m corridor rather than the 30m corridor required for the 
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6MWT, making it easier to perform in the clinical environment.  As with the 6MWT, use of 
%pred distance did not improve the prognostic value of the ISWT.32 
 
Changes in autonomic function has been well described in PAH. Previous investigators have 
shown that autonomic responses to exercise such as peak systolic blood pressure30 and 
chronotropic response29,33 provide prognostic information. Our data confirmed these findings. 
More recently, in an effort to improve the prognostic ability of the 6MWT, interest has been 
shown in the use of post-exercise HRR1 as an additional indicator.  Minai et al. reported 
HRR1 to be prognostic of clinical worsening in patients with idiopathic PAH and patients with 
connective tissue disease-associated PH and to be a stronger predictor of clinical worsening 
than the 6MWD.2,3 However,  HRR1 was not found to be an independent predictor of 
mortality.3 In our study looking at HRR1 after ISWT, we are the first to demonstrate that 
changes in HRR1 are predictive of survival in treatment-naive Group 1 PAH. As in previous 
studies,2,3,34,35 alteration in autonomic control correlated with exercise capacity, and we 
confirmed that HRR1 is not an independent predictor of mortality. Alterations in autonomic 
response to exercise may therefore add supplemental information but the need for a valid 
field exercise reflecting the full range of disease severity is still vital.  
 
In keeping with studies with the 6MWT the use of %change from baseline as an outcome 
measure was not supported by our data (Supplemental Figure 1).  Greatest percentage 
change in distance, both positive and negative, occurred in patients with low baseline ISWT 
distance (Supplemental Table 1). If baseline distance is low, even a large percentage 
improvement may result in a relatively low distance walked at follow-up and survival reflects 
distance walked at follow-up.  In addition, although ǻ,6:'was a predictor of survival, 
bivariate Cox proportional hazard analysis demonstrated that absolute ISWD at follow-up 
was the strongest predictor, and our data support the observation that prognosis depends 
not on how much the patient has improved but rather on how good their current status is.36 
14 
 
The improved sensitivity and specificity of the ISWT at one year compared to baseline 
emphasises the need for assessment at multiple time-points.37 
 
So how could the ISWT be used in clinical practice? Firstly, it performs well as a prognostic 
tool across the spectrum of PAH. It is able to discriminate patients with high versus low risk 
of mortality with increasing sensitivity but decreasing specificity with increasing cut-off points. 
The high sensitivity found at the higher distances allows reassurance to be given to those 
patients who walk furthest.  Secondly, the ISWD is sensitive to change and these changes 
where they translate into clinically meaningful outcomes tend to be large (Table 3).  For an 
individual patient, even with mild disease, change in ISWD may reflect an altered risk of 
mortality, and a decline in ISWD should warrant a review of management.     
 
Study limitations 
We studied a large cohort of patients with PAH but this was a single centre study and further 
work to assess the utility of the ISWT in other centres is required. In addition, there was no 
direct comparison of the ISWT with the 6MWT or cardiopulmonary exercise testing as we 
wished to explore the potential value of the ISWT to assess disease severity and detect 
change in PAH before considering a prospective study. The complete data set of baseline 
,6:7¶VZDVXVHGWRGHYHORSWKH,6:7%Dnd model. As there was post hoc theorizing the 
data may have been over-fitted,38 however, internal validation was carried out which 
supported the Band model. 
 
Conclusion 
In a large study we have shown that in patients with PAH the ISWT correlates with disease 
severity, is sensitive to treatment effect, predicts outcome and has no ceiling-effect. We 
propose further work to explore the ISWT as an alternative to the 6MWT in the assessment 
of disease severity and monitoring of patients with PAH.  Disclosure statement: None of 
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FIGURE LEDGENDS 
 
Figure 1 ± Relationship between baseline Incremental Shuttle Walk Test Band and:  CI: 
cardiac index; PVR: pulmonary vascular resistance, RAP: right atrial pressure; SmVO2: 
mixed venous oxygen saturation; %WHO Class 1+2: percentage of patients in World Health 
Organisation functional class I and II (all p<0.001). Band 1:10-30 m; Band 2: 40-120 m; 
Band 3: 130-250 m; Band 4: 260-420 m; Band 5: 430-1020 m. 
 
Figure 2 - Kaplan-Meier survival analysis stratified according to baseline Incremental Shuttle 
Walk Test distance achieved at A) Baseline; B) 1 year 
 
Figure 3 - Kaplan-Meier survival analysis stratified according to baseline Incremental Shuttle 
Walk Test distance in pulmonary arterial hypertension (PAH) subgroups: A) idiopathic PAH; 
B) PAH associated with systemic sclerosis C) PAH associated with congenital heart disease; 
D) in PAH patients >60 years old. 
 
Figure 4 - Kaplan-Meier survival analysis stratified according to: a) highest heart rate; b) 
change in heart rate c) heart rate recovery at 1 minute; d) highest systolic blood pressure 
(SBP); e) change in SBP; f) SBP 3 minute ratio 
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ABBREVIATIONS: 
6MWT  Six minute walking test 
6MWD  Six minute walking test distance 
HR  Heart rate 
HRR1  Heart rate recovery at 1 minute 
ISWT  Incremental shuttle walking test 
ISWD  Incremental shuttle walking test distance 
ISWD%pred Percentage predicted incremental shuttle walking test distance 
KM  Kaplan-Meier 
PAH  Pulmonary arterial hypertension 
PVR  Pulmonary vascular resistance 
RHC  Right heart catheterisation 
RAP  Right atrial pressure 
SBP  Systolic blood pressure 
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Table 1. Baseline characteristics  
 
 
Presented as mean±SD for parametric data and * median (interquartile range) for 
nonparametric data. SSc: systemic sclerosis; CHD: congenital heart disease; PAH-CTD-
nonSSc: pulmonary arterial hypertension in association with connective tissue disease 
excluding systemic sclerosis: Other: includes other forms of PAH including portal-pulmonary 
PAH and HIV associated PAH; WHO FC: World Health Organization functional class; 
mRAP: mean right atrial pressure; mPAP: mean pulmonary artery pressure; CI: cardiac 
index;  PVR: pulmonary vascular resistance; SmVO2: mixed venous oxygen saturation; 
FEV1: forced expiratory volume in 1 second; % pred: % predicted; FVC: forced vital 
capacity; TL,CO: transfer factor of the lung for carbon monoxide; ISWT: Incremental Shuttle 
Walk Test;  # right heart catheterisation not routinely performed in patients with PAH 
associated with congenital heart disease.  
 
Overall 
 
(n=418) 
Idiopathic-
PAH 
(n=133) 
PAH-SSc 
 
(n=120) 
PAH-
CHD# 
 
(n=119) 
PAH- 
CTD-
nonSSc 
(n=24) 
Other 
 
(n=22) 
Female n (%) 307(73) 87(65) 105(88) 83(70) 19(79) 12(55) 
Age  years 55±17 54±17 66±9 46±18 55±18 52±14 
WHO FC  I+II / 
III+IV (%) 22/78 15/85 21/79 34/64 8/92 14/86 
mRAP mmHg * 8.0(7.0) 10.0(8.0) 8.0(6.0)  7.0(7.0) 9.0(6.0) 
mPAP  mmHg 48±13 53±13 43±12  44±12 46±11 
CI  L/min/m2 * 2.7±0.9 2.2(1.0) 2.8(1,7)  3.0(1.2) 3.3(1.1) 
PVR  Wood Unit * 8.7(7.5) 10.5(7.3) 7.0(7.4)  6.7(4.2) 6.3(4.1) 
SmVO2 (%) 63±9 61±9 65±8  64±10 65±10 
FEV1 %pred 79±20 87±16 84±16 67±20 75±15 69±20 
FVC %pred 90±22 97±19 98±17 76±24 87±17 81±18 
FEV1/FVC (%) 73±10 75±9 71±10 74±12 73±12 70±11 
Tlco %pred 55±23 53±20 41±10 75±25 46±12 57±12 
ISWT Distance m 
* 
140(210) 140(230) 130(180) 190(160) 115(145) 190(238) 
ISWT time 
minutes * 3.7(3.2) 3.5(3.8) 3.5(2.9) 4.3(2.5) 3.1(2.5) 4.3(3.7) 
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Table 2. Analysis of ISWD versus 1-, 2- and 3-year survival 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
ISWD cut-off Sensitivity Specificity PPV NPV 
 
    
One year survival   
>30m 34 88 27 91 
>120m 70 61 19 94 
>250m 92 33 15 97 
>420m 100 10 12 100 
     
Two year survival   
>30m 28 90 40 83 
>120m 65 64 31 88 
>250m 89 36 26 93 
>420m 100 11 22 100 
 
    
Three year survival    
>30m 27 92 62 72 
>120m 65 69 51 80 
>250m 93 23 37 88 
>420m 98 11 35 92 
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Table 3.   Change in Incremental Shuttle Walk distance at 1 year 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Band 1:10-30m, equivalent to 0.50 m/s; Band 2: 40-120m, equivalent to 0.67-0.84 m/s; Band 
3: 130-250m, equivalent to 1.01-1.18 m/s; Band 4: 260-420m, equivalent to 1.35-1.52m/s; 
Band 5: 430-1020m, equivalent to 1.69-2.37 m/s. 
     n % Mean Median 
All               Improve >40m   68 32 111 90 
 Stable  -20 to +40m 
 74 35 8 0 
 Decline > -20m 
   68 32 -82 -65 
 Overall 
 210  12 0 
 
Band 1       Improve >40m 
 9 41 156 120 
 Stable  -20 to +40m 
 11 50 21 20 
 Decline > -20m 
 2 9 -30 -30 
 Overall 
 22  71 40 
Band 2       Improve >40m 
 18 32 101 90 
 Stable  -20 to +40m 
 22 38 10 10 
 Decline > -20m 
 17 30 -49 -40 
 Overall 
 57  21 10 
 
Band 3       Improve >40m 
 17 28 99 90 
 Stable  -20 to +40m 
 20 33 4 40 
 Decline > -20m 
 24 39 -71 -65 
 Overall 
 61  1 -10 
 
Band 4       Improve >40m 
 21 37 104 100 
 Stable  -20 to +40m 
 16 29 5 0 
 Decline > -20m 
 19 34 -116 -100 
 Overall 
 56  1 0 
 
Band 5       Improve >40m 
 3 21 147 110 
 Stable  -20 to +40m 
 5 35 -2 0 
 Decline > -20m 
   6 4. -125 -150 
 Overall 
 14  -23 -15 
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